|
|
|
Sanofi Pasteur is now accepting reservations for Fluzone High-Dose Quadrivalent (Influenza Vaccine), Flublok Quadrivalent (Influenza Vaccine), and Fluzone Quadrivalent (Influenza Vaccine) for the 2020-2021 flu season.
|
|
As your reservation process is beginning, we want to recognize your continued loyalty to the Sanofi Pasteur influenza vaccine portfolio and look forward to assisting you in your vaccination efforts during the 2020-2021 flu season. To further assist, we've created a suggested reservation based on the presentations and number of doses you received last season.
|
|
Your 2020-2021 suggested reservation has been assigned reservation number: [XXXXXXXXXX].
|
PRODUCT
CODE
| PRODUCT
| TOTAL UNITS
RESERVED
| TOTAL DOSES
RESERVED
|
| [XXX-XX] |
[XXXXXXXXX] |
[XX] |
[XX] |
|
It is important that you review, adjust (if necessary), and confirm your reservation by March 31, 2020.
Products will not be reserved or shipped until a Fluzone vaccines reservation is confirmed with VaccineShoppe.com®.
|
|
After your reservation is confirmed, you will receive a confirmation email notification.
|
|
All reservations are subject to Sanofi Pasteur’s Terms and Conditions of Sale, including credit review, in effect at the time of reservation confirmation. Copies of which are available upon request or by logging on to VaccineShoppe.com.
|
|
Fluzone Quadrivalent, Flublok Quadrivalent, and Fluzone High-Dose Quadrivalent are vaccines indicated for the active immunization against influenza disease caused by influenza A subtype viruses and influenza type B viruses contained in the vaccine. Fluzone Quadrivalent is approved for use in persons 6 months of age and older. Flublok Quadrivalent is approved for use in persons 18 years of age and older. Fluzone High-Dose Quadrivalent is approved for use in persons 65 years of age and older.
|
|
IMPORTANT SAFETY INFORMATION
|
|
Fluzone Quadrivalent, Flublok Quadrivalent, and Fluzone High-Dose Quadrivalent should not be administered to anyone who has had a severe allergic reaction (e.g., anaphylaxis) to any component of the vaccine (including egg protein for Fluzone Quadrivalent and Fluzone High-Dose Quadrivalent) or after previous dose of the respective vaccine. In addition, Fluzone Quadrivalent and Fluzone High-Dose Quadrivalent should not be administered to anyone who has had a severe allergic reaction after previous dose of any influenza vaccine.
|
|
Appropriate medical treatment and supervision must be available to manage possible anaphylactic reactions following administration of the vaccine.
|
|
If Guillain-Barré syndrome has occurred within 6 weeks following previous influenza vaccination, the decision to give Fluzone Quadrivalent, Flublok Quadrivalent, and Fluzone High-Dose Quadrivalent should be based on careful consideration of the potential benefits and risks.
|
|
If Fluzone Quadrivalent, Flublok Quadrivalent, and Fluzone High-Dose Quadrivalent are administered to immunocompromised persons, including those receiving immunosuppressive therapy, the immune response may be lower than expected.
|
|
Vaccination with Fluzone Quadrivalent, Flublok Quadrivalent, and Fluzone High-Dose Quadrivalent may not protect all recipients.
|
|
For Fluzone Quadrivalent, in children 6 months through 35 months of age, the most common injection-site reactions were pain or tenderness, erythema, and swelling; the most common solicited systemic adverse reactions were irritability, abnormal crying, malaise, drowsiness, appetite loss, myalgia, vomiting, and fever. In children 3 years through 8 years of age, the most common injection-site reactions were pain, erythema, and swelling; the most common solicited systemic adverse reactions were myalgia, malaise, and headache. In adults 18 years and older, the most common injection-site reaction was pain; the most common solicited systemic adverse reactions were myalgia, headache, and malaise.
|
|
For Flublok Quadrivalent, in adults 18 through 49 years of age, the most common injection-site reactions were tenderness and pain; the most common solicited systemic adverse reactions were headache, fatigue, myalgia, and arthralgia. In adults 50 years of age and older, the most common injection-site reactions were tenderness and pain; the most common solicited systemic adverse reactions were headache, and fatigue.
|
|
For Fluzone High-Dose Quadrivalent, in adults 65 years of age and older, the most common injection-site reaction was pain; the most common solicited systemic adverse reactions were myalgia, headache and malaise.
|
|
For Fluzone Quadrivalent, Flublok Quadrivalent, and Fluzone High-Dose Quadrivalent, other adverse reactions may occur.
|
If any of the information above is incorrect,
please log on to VaccineShoppe.com
or call 1-800-VACCINE (1-800-822-2463).
|
|
|
|
SANOFI PASTEUR
Discovery Drive
Swiftwater, Pennsylvania 18370
www.sanofi.us
|
|
|
|
Please do not reply to this message. Replies to this message are routed to an unmonitored mailbox.
|
|
If you have questions, please visit Customer Support at VaccineShoppe.com® or call 1-800-VACCINE (1-800-822-2463).
|
|
Colorado Prescribers may click here for Wholesale Acquisition Cost Price Disclosure Information.
|
|
To be removed from our mailing list, please click here.
|
|
©2019 Sanofi Pasteur Inc.
|
|
|
|
